<p>Docetaxel is a microtubule inhibitor indicated for:</p>

<ul>
	<li><strong>Breast Cancer (BC)</strong>: single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC</li>
	<li><strong>Non-small Cell Lung Cancer (NSCLC)</strong>: single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC</li>
	<li><strong>Castration-Resistant Prostate Cancer (CRPC)</strong>: with prednisone in metastatic castration-resistant prostate cancer</li>
	<li><strong>Gastric Adenocarcinoma (GC)</strong>: with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction</li>
	<li><strong>Squamous Cell Carcinoma of the Head and Neck (SCCHN)</strong>: with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN</li>
</ul>